Speakers: Scott Stirn (Neurocrine Biosciences)
Organizers: Salma Sarwary
Date: 2018-12-11
Time: 11:00-13:30 Pacific Time
Registration fee: (USD): Food: $0.
Location: Lilly Biotechnology Center Eli Lilly and Company 10290 Campus Point Dr. San Diego, CA, 92121
Major Sponsor: (1)Catalent Pharma Solutions
Vendor show vendors registered to date: (11)Triclinic Labs; ACD/Labs; ActBio; AGILENT TECHNOLOGIES; Averica Discovery Services; Avista Pharma Solutions, Inc.; Beckman Coulter; BioDuro; IRISYS; MicroConstants; Sekisui XenoTech, LLC
Registration: http://www.PBSS.org
Registration deadline:2018-12-11  (it will close sooner if the seating cap is reached)

About the Topic

My talk will focus on the importance of form selection and its impact on formulation development of new chemical entities. Gathering and interpreting physical/chemical characteristics on different forms of NCEs can provide valuable insights on the developability of a particular molecule. This information can be utilized to choose the form with the highest likelihood of success from a formulation development perspective. These characteristics can also provide an early clue on the formulation techniques that will need to be used to produce a drug product that meets the need of a target product profile.

Scott Stirn

I graduated from the University of Arizona with a B.S. in Chemistry and I am on track to receive my M.S.J. in Intellectual Property from Seton Hall Law School in May. I started my career at Arena Pharmaceuticals where I worked in the preformulation group under a PhD crystallographer for six years. I focused on form selection through salt/co-crystal screening and physical characterization. After Arena I worked at a small start-up company named NexBio Inc. where I helped develop a lyophilization technology that created microshperes to enabled high-concentration drug loads for injectable formulations of monoclonal antibodies. I moved on to Celgene where I continued to work on mAb formulations and also worked in the prep-HPLC group where we isolated targeted small molecules through prep-HPLC techniques. I established a material science group for Celgene's San Diego site that helped medicinal chemist optimize form selection of their lead compounds. In 2013 I took a job at Pharmatek Laboratories, Inc. where I created a preformulation group that managed many different projects supporting injectable, opthalmic, and oral clinical drug candidates from clients in the pharmaceutical industry. Finally, I was hired by Neurocrine Biosciences in the beginning of 2016 to develop a preformulation and material science group to support all preclinical and clinical projects. I am currently the Director of the Preformulation and Material Science group.